SAREUM HLDGS LS-0125
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in … Read more
SAREUM HLDGS LS-0125 (RYH0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SAREUM HLDGS LS-0125 (RYH0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SAREUM HLDGS LS-0125 - Net Assets Trend (None–None)
This chart illustrates how SAREUM HLDGS LS-0125's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SAREUM HLDGS LS-0125 (None–None)
The table below shows the annual net assets of SAREUM HLDGS LS-0125 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SAREUM HLDGS LS-0125's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SAREUM HLDGS LS-0125 Competitors by Market Cap
The table below lists competitors of SAREUM HLDGS LS-0125 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kwang Myung El
KO:017040
|
$17.74 Million |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
$17.74 Million |
|
Eildon Capital Group
AU:EDC
|
$17.75 Million |
|
SYSTEM1 GROUP LS-01
F:BBA
|
$17.77 Million |
|
P5X0
F:P5X0
|
$17.73 Million |
|
Hotel Holiday Garden
TW:2702
|
$17.73 Million |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
$17.73 Million |
|
ASTech Co., Ltd.
KQ:453860
|
$17.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SAREUM HLDGS LS-0125's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SAREUM HLDGS LS-0125's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SAREUM HLDGS LS-0125 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SAREUM HLDGS LS-0125's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SAREUM HLDGS LS-0125 (RYH0) | €- | N/A | N/A | $17.74 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |